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Purpose: Systemic treatment with adenosine receptor antagonists has been reported to affect the biochemistry and
ultrastructure of rabbit sclera. This study was conducted to determine whether adenosine receptors (ADORs) are present
in human scleral fibroblasts (HSF).
Methods: Primary HSF were cultured in vitro and identified with anti-vimentin, anti-keratin, anti-desmin, and anti-S-100
antibodies. Confocal fluorescence microscopy was used to study the distribution of ADORs in the HSF cell lines and in
the frozen human scleral sections. ADOR protein expression in HSF and human sclera was confirmed by western blot
analysis of cell lysates.
Results: ADORs were expressed in both HSF and human sclera. This was confirmed by western blot. ADORA1 expression
was concentrated in the nucleus. ADORA2A was concentrated mainly in one side of the cytoplasm, and ADORA2B was
found both in the nucleus and the cytoplasm. ADORA3 was expressed weakly in the cytoplasm.
Conclusions: All four subtypes of ADOR were found in HSF and may play a role in scleral remodeling.
Scleral  fibroblasts  are  involved  in  scleral  remodeling
during axial elongation in myopia. In myopic eyes, the sclera
is thinner and the diameter of collagen fibrils in the posterior
sclera are smaller compared with normal eyes [1-4]. Chronic
treatment of rabbits with the non-selective adenosine receptor
(ADOR) antagonist, 7-methylxanthine, results in a significant
increase  in  the  scleral  concentration  of  collagen  and  an
increase in the diameter of the collagen fibrils in the posterior
sclera [5]. Furthermore, results from a small scale clinical trial
suggest that systemic treatment with 7-methylxanthine slows
down the elongation rate of the eye in myopic children [6]. It
is  therefore  possible  that  ADORs  play  a  role  in  scleral
remodeling in progressive myopia.
ADORs belong to the superfamily of guanine nucleotide-
binding  G-protein-coupled  receptors  that  are  ubiquitously
expressed in a wide variety of tissues. The family includes
four receptor subtypes, ADORA1, ADORA2A, ADORA2B,
and ADORA3 [7].
ADORA1 and ADORA2 have been associated with the
regulation  of  the  intraocular  pressure  in  rabbits  [8]  and
monkeys  [9].  ADORA1,  ADORA2A,  and  ADORA2B
mRNA have been demonstrated to be present in the ciliary
processes  and  retina  of  rat  eyes,  although  no  significant
expression of ADORA3 mRNA was found [10]. Until now,
the presence of ADORs in the human sclera has not been
confirmed. This study was conducted to determine whether
ADORs are present in human scleral fibroblasts (HSF).
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METHODS
Materials: Dulbecco’s modified Eagle's medium plus Ham’s
nutrient mixture F-12 (DMEM/F12), Hank's balanced salt
solution  (HBSS),  fetal  bovine  serum  (FBS),  phosphate
buffered saline (PBS), and trypsin were purchased from Gibco
(Grand Island, NY). Plastic tissue culture dishes, chamber
slides,  and  24  well  plates  were  obtained  from  Corning
(Corning  Ltd,  Tokyo,  Japan).  1X  antibiotic/antimycotic
(penicillin-streptomycin  solution)  was  obtained  from
Invitrogen (Invitrogen Corp, Carlsbad, CA). Anti-ADORA1,
anti-ADORA2A,  anti-ADORA2B,  and  anti-ADORA3
antibodies  (rabbit  pAb)  were  obtained  from  Chemicon
(Chemicon International Inc., Temecula, CA). Anti-vimentin,
anti-keratin,  anti-desmin,  anti-S-100  antibodies,  and
fluorescent  secondary  antibody  were  obtained  from
Zhongshan  Goldenbridge  (Zhongshan  Goldenbridge
Biotechnology  Co  Ltd,  Bejing,  China).  BCA  kits  were
obtained  from  Shenneng  Bocai  (Shenneng  Bocai
Biotechnology Co. Ltd, Shanghai, China). Propidium iodide
(PI),  optimum  cutting  temperature  compound  (OCT),  and
other chemicals were purchased from Sigma (St. Louis, MO).
Tissue  source:  This  study  was  approved  by  the  Ethics
Committee of Sun Yat-sen University in China and complied
with the tenets of the Declaration of Helsinki for Research
Involving Human Tissue. Four healthy, normal, adult human
eyes from donors ranging 20–25 years of age were obtained
from the eye bank of Zhongshan Ophthalmic Center (Sun Yat-
sen University) and were numbered 1, 2, 3, and 4.
Frozen section of human sclera preparation: From donor
eyeball number 1 and 2, the anterior segment, the choroid, and
the retina were removed. The posterior sclera was cut into
5×5 mm2 pieces, embedded with optimum cutting temperature
compound (OCT), and cut into 5 µm sections at −20 °C. They
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523were then tiled onto carrier slices, fixed with cool acetone for
15 min, air-dried, and kept frozen at −20 °C until use.
Human  scleral  fibroblast  isolation,  culture,  and
identification: Donor eyeball number 3 and 4 were washed
immediately in HBSS containing penicillin (200 µg/ml) and
gentamicin sulfate (400 µg/ml). The retinas and choroids were
removed from the sclera. The sclera was trimmed into pieces
approximately 1×1 mm in size, placed in 75 mm2 plastic
culture bottles in DMEM with 1X antibiotic/antimycotic and
10% FBS, and incubated at 37 °C in a humidified incubator
containing 5% CO2. The growth medium was changed twice
a week. When a heavy primary monolayer was achieved, cells
were trypsinized in 0.25% trypsin/EDTA solution in PBS at
room temperature for 2 min and subcultured at a split ratio of
1:3 in a 75 mm2 plastic bottle. The third passage of fibroblasts
was used for this experiment. The fibroblasts were grown on
cover glasses in six well plates until 70%–80% confluence
occurred. The cells were washed with PBS three times, fixed
with cool acetone for 15 min, air-dried, and kept frozen at
−20 °C until use.
The purity of fibroblast cell cultures was confirmed by
staining  for  vimentin  and  stain  resistance  for  cytokeratin,
desmin,  and  S-100  in  the  indirect  immunofluorescence
procedure described below. The morphology of HSF was
observed with light microscopy.
Indirect immunofluorescence: The slices were washed three
times with PBS, covered with 10% normal goat serum diluted
in PBS, and incubated for 20 min at 37 °C. The slices were
then incubated at 4 °C overnight with the primary antibodies
(anti-vimentin,  anti-cytokeratin,  anti-desmin,  anti-S-100,
anti-ADORA1, anti-ADORA2A, anti-ADORA2B, and anti-
ADORA3) diluted at 1:500 in PBS. A negative control was
run in which the cells were incubated in PBS without the
primary antibodies. The slices of both the antibody-treated
and the negative control samples were washed with PBS and
exposed to fluorescein isothiocyanate-conjugated (FITC) goat
anti-rabbit IgG antibodies diluted at 1:50 in PBS at 37 °C for
30 min. The slices were again washed with PBS three times
and added to propidium iodide (PI) for 5 min to stain the cell
nuclei red. Immunofluorescent images were taken using a
Figure 1. Identification of HSF with vimentin, keratin, desmin, and S-100. PI dyed the nucleus (red) and the FITC-marked secondary antibody
(green). A: Vimentin antibody was added to primary cultured HSF migrating from a piece of sclera tissue. B: Negative controls used FITC-
marked secondary antibodies of HSF. C: Vimentin is strongly expressed in the cytoplasm of HSF. D,E,F: Keratin, desmin, and S-100 protein
are not expressed in the cytoplasm or nucleus of HSF. Magnification: 200X.
Molecular Vision 2008; 14:523-529 <http://www.molvis.org/molvis/v14/a63> © 2008 Molecular Vision
524Figure 2. Distribution of ADORA1, ADORA2A, ADORA2B, and ADORA3 in HSF in vitro using indirect immunofluorescence. FITC-marked
the secondary antibody (green; 1) and PI dyed the nucleus (red; 2). (1) and (2) are combined into (3). ADORA1 is concentrated in the nucleus
of HSF (A1-A3). ADORA2A is mainly distributed on one side of the HSF cytoplasm (B1-B3). ADORA2B is distributed in the cytoplasm
and nucleus of HSF (C1-C3). ADORA3 is weakly expressed in the cytoplasm of HSF (D1-D3). Magnification: 400X.
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525Figure 3. Distribution of ADORA1, ADORA2A, ADORA2B, and ADORA3 in human sclera using indirect immunofluorescence. FITC-
marked the secondary antibody (green; 1) and PI dyed the nucleus (red; 2). (1) and (2) are combined into (3). ADORA1 is strongly condensed
in the nucleus of HSF (A1-A3). ADORA2A is mainly distributed on one side of the HSF cytoplasm (B1-B3). ADORA2B and ADORA3 are
distributed in the cytoplasm of HSF (C1-C3 and D1-D3).
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526confocal  microscope  (LSM  510  META,  Carl  Zeiss,  Jena,
Germany).
Western blot analysis: HSF were cultured in DMEM/F12 for
48 h and harvested; human sclera were shivered into pieces
and centrifuged (15,000x g) at 4 °C for 1 h. HSF lysates were
prepared in a lysis buffer and boiled in a sample buffer for 5
min. The protein concentration was detected by BAC kits.
Protein  (40  μg)  was  loaded  in  each  lane  of  10%  SDS-
polyacrylamide  gels,  transferred  onto  polyvinylidene
difluoride membranes for electrophoresis, blocked in TBST
(5% fat-free dry milk, 0.1% Tween 20, 150mM NaCl, and
50 mM Tris at pH 7.5) for 1 h. The membranes were exposed
to  1  µg/ml  of  anti-ADORA1,  anti-ADORA2A,  anti-
ADORA2B,  and  anti-ADORA3  polyclonal  antibody  and
incubated overnight at 4 °C. They were then incubated with a
secondary horseradish peroxidase-labeled antibody for 1 h.
Protein  bands  were  visualized  with  the  use  of  a
chemiluminescence  Phototope(R)-HRP  Western  Blot
detection system (Cell Signaling Technology, Inc., Danvers,
MA) and exposed onto a negative film, developed, and fixed.
The film was scanned and analyzed with Gel-Pro Analyzer
software.
Statistical analysis: Statistical analysis was performed using
Student's  two-tailed  t-test  and  by  analysis  of  variance
(ANOVA) followed by the Sheffe F-test.
RESULTS
Identification  of  human  scleral  fibroblasts:  As  shown  in
Figure 1, the cytoplasm of the studied cells strongly expressed
vimentin protein but did not express keratin, desmin, or S-100,
and the cells were thereby identified as fibroblasts. The HSF
migrated from the pieces of sclera tissue and populated the
surroundings. The cells exhibited a uniform, fusiform shape.
Cell growth was compact and arranged in a vortex or radiating
pattern.
Expression  of  adenosine  receptors  in  human  scleral
fibroblast:  As  shown  in  Figure  2,  ADORA1  was  only
expressed and distributed in the nucleus of HSF. ADORA2A
was expressed mainly on one side of the cytoplasm of HSF.
ADORA2B was uniformly expressed in the cytoplasm and
nucleus of HSF. ADORA3 was slightly expressed nn the
cytoplasm of HSF.
Expression of adenosine receptors in human sclera: As shown
in Figure 3, ADORA1 was expressed mainly in the nucleus
of  HSF  and  slightly  expressed  in  the  cytoplasm  of  HSF.
ADORA2A  was  expressed  mainly  on  one  side  of  the
cytoplasm of HSF. ADORA2B and ADORA3 were uniformly
expressed in the extracellular matrix and the cytoplasm of
HSF.
Western blot results: As shown in Figure 4, four subtypes of
ADOR protein were found in HSF and human sclera. The
approximate molecular weight for ADORA1, ADORA2A,
ADORA2B, and ADORA3 was 39 kDa, 45 kDa, 52 kDa, and
36  kDa,  respectively.  ADORA1  and  ADORA2B  were
strongly  expressed  in  both  the  HSF  and  human  sclera.
ADORA2A and ADORA3 were also expressed in both the
HSF  and  human  sclera  but  only  weakly  in  the  latter.  In
particular, ADORA3 was very weakly expressed in the human
sclera.
DISCUSSION
The identity of the cultured HSF was confirmed by positive
indirect immunofluorescence reactivity to vimentin and by
lack  of  reactivity  to  keratin,  S-100  protein,  and  desmin
[11-14].
The  expression  of  ADORs  in  HSF  has  not  been
previously reported. Our finding of only a weak expression of
ADORA3 in HSF is in accordance with earlier findings of no
ADORA3 expression in rat eyes [9]. The varying localization
of the ADORs in HSF, such as ADORA1 in the nucleus,
ADORA2A in one side of the cytoplasm, ADORA2B weakly
expressed  in  both  cytoplasm  and  nuclei,  and  ADORA3
weakly  expressed  in  the  cytoplasm,  can  be  ascribed  to
different  cellular  functions  of  these  receptor  subtypes.
Different subcellular localization of adenosine receptors has
been reported previously. In both dendrites and axons of rat
striatal  neurons,  ultrastructural  analysis  has  identified  the
adenosine  ADORA2A  receptor  localized  in  the  plasma
membrane,  throughout  the  cytoplasm,  and  around
intracellular membranous structures [15].
Adenosine, a product of ATP catabolism, is a potent
regulator of a multitude of cellular and organ functions via
interaction  with  ADORs  present  in  every  type  of  tissue.
ADORs are coupled to mitogen-activated protein kinases and
Figure 4. Four subtypes of ADOR expressed in HSF and human
sclera (HS). The marker ladder is from 10 kDa to 200 kDa. The
molecular weight of ADORA1 is about 39 kDa, ADORA2A is 45
kDa, ADORA2B is about 52 kDa, and ADORA3 is nearly 36 kDa.
ADORA1 and ADORA2B are strongly expressed in both the HSF
and human sclera, but ADORA2A and ADORA3 are only weakly
expressed in the human sclera.
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527may  therefore  play  a  role  in  cell  cycle  progression,
proliferation, and differentiation [16].
Adenosine plays an important role as a neuromodulator
in mammals but also affects supportive cells in the central
nervous  system.  Thus,  adenosine  induces  rapid
glycogenolysis followed by increased glycogen synthesis in
primary  astrocytes.  The  effect  seems  to  be  mediated  by
ADORA2B adenosine receptors. In response to traumatic and
chemical brain injury involving the upregulation of enzymes,
cytoskeletal proteins, transforming growth factor β (TGFβ),
nerve growth factor, basic growth factor, and growth factor
receptors, reactive astrogliosis is mediated by ADORA2A and
possibly  ADORA3  whereas  ADORA1  inhibits  astrocyte
proliferation  [17].  ADORA2A  antagonists  prevent
astrogliosis induced in vitro by basic fibroblast growth factors
[18].
ADORA2A agonists enhance the rate of matrix formation
in  wound  healing.  Human  dermal  fibroblasts  express
ADORA1, ADORA2A, and ADORA2B [19]. ADORA2B on
synovial  fibroblasts  diminish  the  release  of  matrix
metalloproteases, and on pulmonary fibroblasts, they increase
collagen  production  and  diminish  metalloprotease
production.  Similarly,  in  human  skin  and  liver  cells,
ADORA2A  promotes  collagen  synthesis  and  diminishes
metalloprotease  secretion  [20].  ADORA2B,  however,
diminishes  collagen  production  and  cell  proliferation  of
cardiac fibroblasts [21,22]. Overstimulation of ADORA2A is
probably a pathogenetic factor in scleroderma and hepatic
fibrosis [19]. The cytokine, TGF-β, upregulates adenosine
ADORA2A  expression  in  human  dermal  fibroblasts  [19].
Interestingly,  downregulation  of  TGF-β  is  observed  in
mammals during the progression of myopia induced by form
deprivation [23].
Topically applied muscarine acetylcholine antagonists
have been shown to reduce myopia progression and axial eye
growth [24-26]. The mechanism of action of atropine and
pirenzepine  has  not  been  established,  but  M1  to  M5
muscarinic acetylcholine receptors have been identified in
HSF, and HSF are therefore a potential site of action of these
drugs [27-29]. M2, M4, and M5 muscarinics have also been
identified in human skin fibroblasts [30]. Interestingly, in
many cell systems, muscarinics and ADORs interact. Thus,
M2  muscarinic  receptor  activation  inhibits  ADOR-evoked
relaxation of the rat detrusor muscle, and M1 muscarinic and
ADORA2A receptors are mutually exclusive at facilitating
acetylcholine release from rat motor endplate motoneurons
[31,32]. In the central nervous system, ADORA2A agonists
increase  muscarinic  acetylcholine  receptor-mediated
neurotransmission [33,34], and low doses of the non-selective
ADOR antagonist caffeine enhances the anticataleptic actions
of  muscarinic  antagonists  in  rats  [35].  It  is  therefore
conceivable  that  adenosine  and  muscarinic  acetylcholine
receptors on scleral fibroblasts also interact and that blocking
of ADORs induces extracellular matrix composition changes
due to modulation of muscarinic acetylcholine transmission
or vice versa. It is likewise conceivable that simultaneous
blocking  of  both  adenosine  and  muscarinic  acetylcholine
receptors  has  an  additive  effect  on  the  production  of
extracellular matrix by the scleral fibroblast.
The finding of ADOR expression in HSF signified that
adenosine and ADOR may play a role in scleral remodeling
during eye growth. Further research on the role of different
ADOR subtypes is needed.
ACKNOWLEDGMENTS
The authors would like to thank Dr. Nie Haohui and Mr. Xu
Xiaoping for their excellent technical assistance.
REFERENCES
1. Kusakari T, Sato T, Tokoro T. Regional scleral changes in form-
deprivation  myopia  in  chicks.  Exp  Eye  Res  1997;
64:465-76. [PMID: 9196399]
2. McBrien NA, Gentle A. Role of the sclera in the development
and pathological complications of myopia. Prog Retin Eye
Res 2003; 22:307-38. [PMID: 12852489]
3. McBrien  NA,  Cornell  LM,  Gentle  A.  Structural  and
ultrastructural changes to the sclera in a mammalian model of
high myopia. Invest Ophthalmol Vis Sci 2001; 42:2179-87.
[PMID: 11527928]
4. McBrien NA, Lawlor P, Gentle A. Scleral remodeling during
the development of and recovery from axial myopia in the tree
shrew. Invest Ophthalmol Vis Sci 2000; 41:3713-9. [PMID:
11053267]
5. Trier  K,  Olsen  EB,  Kobayashi  T,  Ribel-Madsen  SM.
Biochemical and ultrastructural changes in rabbit sclera after
treatment  with  7-methylxanthine,  theobromine,
acetazolamide,  or  L-ornithine.  Br  J  Ophthalmol  1999;
83:1370-5. [PMID: 10574816]
6. Trier KR-MS. Effect of 7-Methylxanthine on Axial growth in
myopic Children - 24 Months Follow-Up. In: ARVO Annual
Meeting. Fort Lauderdale, FL; 2007.
7. Yaar R, Jones MR, Chen JF, Ravid K. Animal models for the
study of adenosine receptor function. J Cell Physiol 2005;
202:9-20. [PMID: 15389588]
8. Crosson CE, DeBenedetto R, Gidday JM. Functional evidence
for  retinal  adenosine  receptors.  J  Ocul  Pharmacol  1994;
10:499-507. [PMID: 8083569]
9. Tian  B,  Gabelt  BT,  Crosson  CE,  Kaufman  PL.  Effects  of
adenosine  agonists  on  intraocular  pressure  and  aqueous
humor dynamics in cynomolgus monkeys. Exp Eye Res 1997;
64:979-89. [PMID: 9301479]
10. Kvanta  A,  Seregard  S,  Sejersen  S,  Kull  B,  Fredholm  BB.
Localization of adenosine receptor messenger RNAs in the
rat eye. Exp Eye Res 1997; 65:595-602. [PMID: 9367639]
11. Bozanic  D,  Bocina  I,  Saraga-Babic  M.  Involvement  of
cytoskeletal  proteins  and  growth  factor  receptors  during
development of the human eye. Anat Embryol (Berl) 2006;
211:367-77. [PMID: 16586110]
12. Arsenijevic  Y,  Taverney  N,  Kostic  C,  Tekaya  M,  Riva  F,
Zografos L, Schorderet D, Munier F. Non-neural regions of
Molecular Vision 2008; 14:523-529 <http://www.molvis.org/molvis/v14/a63> © 2008 Molecular Vision
528the adult human eye: a potential source of neurons? Invest
Ophthalmol Vis Sci 2003; 44:799-807. [PMID: 12556416]
13. Shams NB, Huggins EM Jr, Sigel MM. Regulation of mitogen-
driven lymphoreticular cell activation by human corneal cells
and interleukin-1. Cornea 1993; 12:46-53. [PMID: 8458231]
14. Shams  NB,  Sigel  MM,  Davis  RM.  Interferon-gamma,
Staphylococcus  aureus,  and  lipopolysaccharide/silica
enhance  interleukin-1  beta  production  by  human  corneal
cells. Reg Immunol 1989; 2:136-48. [PMID: 2484299]
15. Hettinger  BD,  Lee  A,  Linden  J,  Rosin  DL.  Ultrastructural
localization of adenosine A2A receptors suggests multiple
cellular sites for modulation of GABAergic neurons in rat
striatum.  J  Comp  Neurol  2001;  431:331-46.  [PMID:
11170009]
16. Schulte G, Fredholm BB. Signalling from adenosine receptors
to  mitogen-activated  protein  kinases.  Cell  Signal  2003;
15:813-27. [PMID: 12834807]
17. Dare E, Schulte G, Karovic O, Hammarberg C, Fredholm BB.
Modulation of glial cell functions by adenosine receptors.
Physiol Behav 2007; 92:15-20. [PMID: 17574632]
18. Brambilla R, Cottini L, Fumagalli M, Ceruti S, Abbracchio MP.
Blockade  of  A2A  adenosine  receptors  prevents  basic
fibroblast growth factor-induced reactive astrogliosis in rat
striatal  primary  astrocytes.  Glia  2003;  43:190-4.  [PMID:
12838511]
19. Chan ES, Fernandez P, Merchant AA, Montesinos MC, Trzaska
S, Desai A, Tung CF, Khoa DN, Pillinger MH, Reiss AB,
Tomic-Canic M, Chen JF, Schwarzschild MA, Cronstein BN.
Adenosine  A2A  receptors  in  diffuse  dermal  fibrosis:
pathogenic role in human dermal fibroblasts and in a murine
model of scleroderma. Arthritis Rheum 2006; 54:2632-42.
[PMID: 16871530]
20. Cronstein  BM.  Adenosine  receptors  and  wound  healing,
revised.  ScientificWorldJournal  2006;  6:984-91.  [PMID:
16921444]
21. Dubey  RK,  Gillespie  DG,  Jackson  EK.  Adenosine  inhibits
collagen and protein synthesis in cardiac fibroblasts: role of
A2B  receptors.  Hypertension  1998;  31:943-8.  [PMID:
9535419]
22. Chen Y, Epperson S, Makhsudova L, Ito B, Suarez J, Dillmann
W, Villarreal F. Functional effects of enhancing or silencing
adenosine A2b receptors in cardiac fibroblasts. Am J Physiol
Heart Circ Physiol 2004; 287:H2478-86. [PMID: 15284071]
23. Jobling  AI,  Nguyen  M,  Gentle  A,  McBrien  NA.  Isoform-
specific changes in scleral transforming growth factor-beta
expression and the regulation of collagen synthesis during
myopia  progression.  J  Biol  Chem  2004;  279:18121-6.
[PMID: 14752095]
24. Fan DS, Lam DS, Chan CK, Fan AH, Cheung EY, Rao SK.
Topical atropine in retarding myopic progression and axial
length growth in children with moderate to severe myopia: a
pilot  study.  Jpn  J  Ophthalmol  2007;  51:27-33.  [PMID:
17295137]
25. Tan DT, Lam DS, Chua WH, Shu-Ping DF, Crockett RS. One-
year  multicenter,  double-masked,  placebo-controlled,
parallel  safety  and  efficacy  study  of  2%  pirenzepine
ophthalmic  gel  in  children  with  myopia.  Ophthalmology
2005; 112:84-91. [PMID: 15629825]
26. Siatkowski RM, Cotter S, Miller JM, Scher CA, Crockett RS,
Novack  GD.  Safety  and  efficacy  of  2%  pirenzepine
ophthalmic gel in children with myopia: a 1-year, multicenter,
double-masked,  placebo-controlled  parallel  study.  Arch
Ophthalmol 2004; 122:1667-74. [PMID: 15534128]
27. Lind  GJ,  Chew  SJ,  Marzani  D,  Wallman  J.  Muscarinic
acetylcholine  receptor  antagonists  inhibit  chick  scleral
chondrocytes. Invest Ophthalmol Vis Sci 1998; 39:2217-31.
[PMID: 9804129]
28. Liu  Q,  Wu  J,  Wang  X,  Zeng  J.  Changes  in  muscarinic
acetylcholine receptor expression in form deprivation myopia
in guinea pigs. Mol Vis 2007; 13:1234-44. [PMID: 17679952]
29. Qu J, Zhou X, Xie R, Zhang L, Hu D, Li H, Lu F. The presence
of m1 to m5 receptors in human sclera: evidence of the sclera
as  a  potential  site  of  action  for  muscarinic  receptor
antagonists.  Curr  Eye  Res  2006;  31:587-97.  [PMID:
16877267]
30. Buchli R, Ndoye A, Rodriguez JG, Zia S, Webber RJ, Grando
SA. Human skin fibroblasts express m2, m4, and m5 subtypes
of muscarinic acetylcholine receptors. J Cell Biochem 1999;
74:264-77. [PMID: 10404395]
31. Giglio D, Delbro DS, Tobin G. Postjunctional modulation by
muscarinic  M2  receptors  of  responses  to  electrical  field
stimulation  of  rat  detrusor  muscle  preparations.  Auton
Autacoid Pharmacol 2005; 25:113-20. [PMID: 15955031]
32. Oliveira L, Correia-de-Sa P. Protein kinase A and Ca(v)1 (L-
Type) channels are common targets to facilitatory adenosine
A2A  and  muscarinic  M1  receptors  on  rat  motoneurons.
Neurosignals 2005; 14:262-72. [PMID: 16301841]
33. Marks GA, Shaffery JP, Speciale SG, Birabil CG. Enhancement
of rapid eye movement sleep in the rat by actions at A1 and
A2a  adenosine  receptor  subtypes  with  a  differential
sensitivity  to  atropine.  Neuroscience  2003;  116:913-20.
[PMID: 12573729]
34. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois
JM. Adenosine A2A receptor knockout mice are partially
protected against drug-induced catalepsy. Neuroreport 2001;
12:983-6. [PMID: 11303773]
35. Moo-Puc RE, Gongora-Alfaro JL, Alvarez-Cervera FJ, Pineda
JC, Arankowsky-Sandoval G, Heredia-Lopez F. Caffeine and
muscarinic antagonists act in synergy to inhibit haloperidol-
induced catalepsy. Neuropharmacology 2003; 45:493-503.
[PMID: 12907310]
Molecular Vision 2008; 14:523-529 <http://www.molvis.org/molvis/v14/a63> © 2008 Molecular Vision
The print version of this article was created on 14 March 2008. This reflects all typographical corrections and errata to the article
through that date. Details of any changes may be found in the online version of the article.
529